becton dickinson co nyse qqq
becton dickinson deliv slightli ahead expect
updat forecast estim aug
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim aug
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
becton dickinson certainli keen abandon predict
compani monik surpris investor commun three
year ago first major acquisit oper histori
bd doubl carefus deal size purchas
 bard big fan bard believ addit
higher-growth busi along reinvigor perform
bd legaci busi push compani
organ revenu growth improv may seem
particularli impress nonetheless sizeabl jump
compani compet product area histor
experienc growth broader medic sector bd
product pipelin potenti expand
overal size market posit compani full-suit
product solut vendor
essenti natur bd medic product given
compani ampl cash flow reinvest bd made
consciou effort deploy capit bolster offer
area diabet inject bioscienc compani
also built massiv presenc emerg market
distribut manufactur network unparallel med
tech world return intern invest becom
evid form improv organ growth compani
increasingli turn acquisit
acquisit carefus first sign bd depart
century-old strategi bolt-on acquisit
bard deal move compani even away comfort
zone bard bring challeng oper area
competit deep-pocket research develop
commit requir carefus product suit provid
mani complementari opportun bd product bard
integr probabl bit challeng said
believ bd allow bard autonomi particularli
pertain spend area pad give us
confid compani postmerg goal revenu
growth synergi line
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
becton dickinson world largest manufactur distributor
medic surgic product needl syring sharps-dispos
unit compani also manufactur diagnost instrument reagent
well flow cytometri cell-imag system revenu
account less compani busi carefus
bd enter medic system infus pump
ventil well procedur solut busi bard deal give
compani presenc urolog vascular oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
becton dickinson deliv slightli ahead
becton dickinson co report strong fiscal third-
quarter result revenu currency-neutr
basi compani slightli tick full-year guidanc
maintain fair valu estim narrow
moat rate share slightli overvalu
area medic segment deliv good result
medic manag solut
busi currency-neutr basi
significantli long-term expect pyxi
es main driver perform aid
chang dispens model medic deliveri
solut also deliv result target vascular
solut bard busi significantli bolster
growth constant exchang rate intervent
busi peripher urolog
busi offset modest weak surgeri unit
geograph segment market solid
emerg market remain key driver
overal growth organ quarter china
compani adjust full-year guidanc upward
revenu line incorpor good third-quart result
strong momentum far fourth quarter
revis forecast upward note underli
growth full year would highest growth
rate compani achiev decad
tighten manag guidanc constant-curr full-
year ep growth line forecast
bd also announc addit appoint former
bard personnel key leadership posit compani
bard peopl charg area
deem particularli impress within bard
product cultur addit leadership
rais fair valu estim per share
follow slight creas organ growth
forecast legaci bd busi detail
assess pluse minus bard
acquisit includ synergi expect peak
million per annum
bard bring lead product portfolio strong
engin onu bd maintain posit
signific integr risk play although
give bd benefit doubt model growth
bard segment next five year along
legaci busi recent increas growth rate
across board larg unchang sever
driver behind recent revis growth forecast first
core medic busi see effect
signific invest firm pipelin
strongest long time origin bd
product suit carefus portfolio medic
dispens pump expand firm
launch innov product across spectrum firm
also expand presenc informat
histor
interconnect import pillar bd new strategi
aim control larger portion care
continuum diseas manag particularli area like
diabet bd alway strong attract
opportun develop world emerg
also rais forecast bd lifesci
diagnost segment still face challeng tripath
busi compani lack scale product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
bull bear scenario respect howev
see volatil futur cash flow given
uncertainti surround bd abil integr
deal unpreced size best-cas
scenario fair valu estim bd per share
foundat bd moat manufactur scale
basic surgic product segment account
half compani busi compani
largest manufactur needles/syring competit
match compani scale make compet price
difficult said compani entir
price-sett busi commoditylik
price increas primarili achiev product mix
decreas matur line off-set higher price new
product introduct bd diagnost busi squar
narrow-moat bucket robust instal base
respons steadi recur revenu provid
switch cost defenc new entrant howev
compani assay becom increasingli commoditis
reliant continu innov off-set price
pressur age portfolio bioscienc segment
would also like receiv narrow moat rate
firm hold lead posit flow cytomet
invest heavili expand presenc broader
cell-therapi market still
lack breadth
capabl peer
carefus narrow moat stem high product
switch cost substanti barrier entri deriv
larg portion revenu product
market leader intraven infus pump
respir ventil
infection-control product carefus maintain
number-on market posit mani product
categori especi infus pump medication-dispens
equip estim hold global
breadth larger player made invest
higher-growth area mainli molecular diagnost
autom expand assay portfolio bd max
schedul launch high-volum molecular system
next year make greater inroad
bd emphasi profit allow expand
oper margin despit on-going price pressur raw
materi inflat although incorpor sizeabl
margin boost current level forecast -- less
basi point per year believ compani
abl extract oper synergi carefus
histor rang bd plausibl scenario outcom
fairli tight due predict natur
medic divis cash flow key driver bull
bear scenario firm revenu growth abil
success integr carefus particular bard
rang revenu growth outcom still fairli
compound annual five-year growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
develop world less pronounc emerg
market particularli carefus brand
cachet initi barrier entri rather low
bard critic variabl bd abil
success navig challeng integr bard
innov aggress natur bd conserv
structur bd compet area
histor virtual zero presenc certain
stage moat benefit presenc
bard portfolio product
view bd moat trend stabl post-acquisit
compani manufactur infrastructur surgic
busi sizeabl hurdl potenti new entrant
competit fairli intens among exist industri
particip primarili commoditis natur
mani firm product compani inabl
consist rais price even line inflat
testament industri tough competit dynam
growth compani manufactur infrastructur
particularli outsid strengthen scale
advantag view overal competit advantag
stabl
share respect infus market particular
rel oligopoli carefus baxter hospira
braun control market new smaller
entrant hard time contend
establish player scale breadth product offer
product familiar hospit familiar
particular brand devic rare switch thank
retrain cost well product process familiar
compani like carefus larg instal base
devic enjoy low custom turnov stream
recur revenu associ dispos long
oper life devic
bard dug narrow moat divers portfolio
differenti product patent protect
innov addit manag done credibl
job ad new product includ new technolog
requir market develop expand bard wide
rang product primarili variou acquisit
firm well posit provid hospit custom
group purchas organ one-stop shop
prospect bundl deal compani abil
make meaning innov key product
foley cathet allow firm stave price
pressur maintain presenc equip shelf
bard solidifi narrow moat relationship
practition vascular surgic urolog
oncolog area tie bard seek cultiv
physician prefer product
compani busi less presenc weaker
diagnost bioscienc area face mani
challeng warrant wide econom moat
carefus busi oligopoli matur domest
market certain would abl deploy
current tactic emerg market bd attempt
expand presenc higher-price-point product
suscept capital-spend fluctuat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
obard bring lead pad franchis
odevelop market fulli convert safeti
mandat convert place eu bd
abil expand mature-market safeti
obd max enjoy strong adopt
test menu grow platform continu
ogrowth compani hospit consum
capit equip product line like remain
weak healthcar provid remain cautiou
cash deploy
challeng keep key leader crucial
obd acquisit strategi new risk compani
avoid transform deal
long histori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
bd leverag financ bard acquisit given
ampl stabl cash flow model bd success
reduc debt load commenc buy-back program
five year financ billion came form
convert prefer stock mandatori convers
forecast prefer convert common fiscal
bd surgic product commoditylik make
differenti virtual non-existent forc firm
compet price field diagnost bioscienc
bd number rival abbott roch
possess greater market reach larger research
develop budget academ govern
spend environ unit state
europ may remain constrain long period
neg affect demand firm research
instrument bard acquisit could challeng
integr much valu deal stem sale
oper synergi well compani abil
retain key bard personnel innov cultur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
compani execut among best industri
term capit alloc view assign bd
exemplari stewardship grade year firm
focus return invest capit wise capit
deploy limit growth acquisit
run major oper mishap
compani success record speak highli
longev bd strong return capit particularli
remark given half firm busi belong
manag appear understand take
basic medic devic
invest go steadili expans
manufactur footprint solidifi scale advantag
competit compani manag expand
presenc basic medic devic maintain robust
return competitor often exit arena
histor bd resist temptat sizeabl
acquisit instead focus fill small product gap
rather market share grab carefus bard
deal departur histor strategi
manag team far deliv promis
particularli impress abil extract
cost synergi low-hang fruit consid
carefus rel bloat cost structur also
manag step far increas growth
core carefus busi histor level
requir bolster exist portfolio
meaning invest leverag
infrastructur deliv carefus product geographi
previous lack capac new long-term
growth target incorpor elev perform
integr bard even challeng consid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
bard portfolio product requir higher capit
intens cautious optimist bd retain
bard key personnel leav cultur intact
result bard remain top-tier player devic
number key bard execut sever segment
post-acquisit bd led ex-bard manag
critic maintain innov cultur
allow bard becom one best-run medic devic
come govern practic compani
shareholder-friendli polici place consid
gener success align corpor perform
execut pay top manag also requir
receiv portion total pay compani stock
disclosur detail compani
histor avoid pollut financi statement
non-gaap adjust though polici chang
larg amortis expens hit incom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
futur within bd high-profil appoint impli
probabl see segment remain bd fold
receiv addit invest futur includ
result revenu currency-neutr basi
includ estim advers impact
chang dispens busi model
maintain fair valu estim narrow moat
area medic segment deliv good result
except medic manag solut
advers affect dispens
revenu recognit chang tough comparison
prior-year period life scienc report growth
constant exchang rate perform aid
significantli strong flu season basi point
intervent busi drug-coat
balloon
biopsi busi deliv solid
perform urolog benefit tender time
geograph segment market
neg affect issu roughli line
forecast emerg market remain key driver
overal growth organ quarter
china still grow strongli despit difficult
compani adjust full-year guidanc
revenu margin line incorpor larg posit
currenc impact updat manag guidanc
growth line forecast assess
synergi expect deal line bd target
intrigu compani announc new
leadership life scienc segment former
senior vice presid presid life scienc
appli market group agil lead bd life
scienc group entir clear segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
fiscal year end septemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
